Welcome to our dedicated page for Astrana Health news (Ticker: ASTH), a resource for investors and traders seeking the latest updates and insights on Astrana Health stock.
Astrana Health Inc. reports developments in physician-centric, technology-enabled healthcare management, including its care delivery infrastructure, proprietary technology platform, and aligned provider networks. The company describes a payer-agnostic, risk-bearing care model designed around coordinated, preventive care and population health management.
Recurring news themes include quarterly and annual financial results, medical cost performance, full-risk contract activity, integration of completed acquisitions, investor-conference presentations, and updates involving governance, capital structure, and operating performance. Company materials also discuss its Care Partners, Care Delivery, and Care Enablement segments.
Foothill Regional Medical Center (NASDAQ: ASTH) received the 2026 Patient Safety Excellence Award™ from Healthgrades, placing it among the top 5% of U.S. hospitals for patient safety. The hospital earned multiple 2025–2026 Healthgrades distinctions, including joint replacement and five-star ratings across several procedures.
Foothill Regional has been a Patient Safety Excellence recipient four consecutive years (2023–2026) and operates a 177-bed acute care facility with 42 pediatric subacute beds in Orange County.
Astrana Health (NASDAQ: ASTH) announced that company leadership will participate in multiple investor conferences in March 2026, including TD Cowen (Boston), Jefferies Value-Based Healthcare (Miami), Barclays (Miami), KeyBanc (virtual) and Oppenheimer (virtual).
Each participation includes scheduled fireside chats and the company said webcast links and presentation materials will be available in the IR Calendar on its investor website.
Astrana Health (NASDAQ: ASTH) reported 2025 total revenue of $3,181.8 million, up 56% year-over-year, adjusted EBITDA of $205.4 million, and free cash flow of $104.5 million. Fourth-quarter revenue was $950.5 million with adjusted EBITDA of $52.5 million. The company filed a Form 12b-25 extension for its 2025 Form 10-K due to a material weakness in internal controls related to acquisition and purchase accounting. The Board increased the share repurchase authorization to $100 million. 2026 guidance targets ~24% revenue growth midpoint and adjusted EBITDA growth at midpoint.
Astrana Health (NASDAQ: ASTH) will release its fourth quarter and full-year 2025 financial results before market open on Monday, March 2, 2026. The company will host a conference call the same day at 5:30 a.m. PT / 8:30 a.m. ET to discuss results. A slide presentation (PDF) will be posted to the IR Calendar page after the release. The call is accessible by dial-in or live webcast, and a recording will be available after the call.
Astrana Health (NASDAQ: ASTH) announced that company leadership will participate in the J.P. Morgan 2026 Healthcare Conference in San Francisco on Monday, January 12, 2026, including a presentation at 5:15 PM PT. The company said a live webcast and related presentation materials will be posted in the IR Calendar on its investor relations website.
Investors can access the webcast and slides via the company's investor relations page at https://ir.astranahealth.com/news-events/ir-calendar.
Astrana Health (NASDAQ: ASTH) reported third quarter 2025 results and completed the Prospect Health acquisition on July 1, 2025. Q3 total revenue was $956.0M, up 100% YoY, and Adjusted EBITDA was $68.5M, up 52% YoY. Nine‑month total revenue was $2,231.2M (+63% YoY) with Adjusted EBITDA of $153.0M (+13% YoY). Net income attributable to Astrana was $0.4M for Q3 and $16.5M for the nine months. Company reiterated strong clinical and cost trends but updated full‑year guidance timing to reflect certain full‑risk contract delays expected to complete in Q1 2026. Updated 2025 guidance: Revenue $3.10–3.18B, Adjusted EBITDA $200–210M.
Astrana Health (NASDAQ: ASTH) will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a conference call the same day at 2:30 p.m. PT / 5:30 p.m. ET to discuss results.
An accompanying PDF slide presentation will be posted on the company's IR Calendar page after the earnings release. Live dial-in numbers are 877-858-9810 and +1 201-689-8517; callers are asked to dial in about five minutes early. The call will be webcast and a recording will be available at the provided webcast link shortly after the call.
Astrana Health (NASDAQ: ASTH), a provider-centric, technology-powered healthcare company, has announced its participation in three major upcoming investor conferences in September 2025:
- Wells Fargo Healthcare Conference (September 3-4)
- Morgan Stanley Global Healthcare Conference (September 9) - Including a Fireside Chat from 5:35 PM to 6:10 PM ET
- Baird Healthcare Conference (September 10)
Astrana Health (NASDAQ: ASTH) reported strong Q2 2025 financial results, with total revenue reaching $654.8 million, up 35% year-over-year, and adjusted EBITDA of $48.1 million. The company's Care Partners segment led growth with revenue of $631.4 million, a 36% increase.
Key highlights include the completion of the Prospect Health acquisition for $707.9 million on July 1, 2025, financed through a five-year delayed draw term loan. The company also strengthened its leadership team with several strategic appointments, including Sherry McBride as COO.
Astrana reiterated its full-year 2025 guidance, projecting total revenue between $3.1-3.3 billion and adjusted EBITDA of $215-225 million, which includes the Prospect Health acquisition impact.
Astrana Health (NASDAQ: ASTH), a provider-centric healthcare technology company, has scheduled its Q2 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 2:30 PM PT/5:30 PM ET on the same day to discuss the results. Participants can join via phone (877-858-9810 or +1 201-689-8517) or webcast. A slide presentation will be available on the company's IR website, and a recording will be accessible after the call.